Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Significant Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 185,700 shares, an increase of 59.0% from the February 28th total of 116,800 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is presently 0.1 days.

Protagenic Therapeutics Trading Down 10.0 %

Shares of PTIX stock traded down $0.03 on Friday, hitting $0.23. The stock had a trading volume of 70,972 shares, compared to its average volume of 638,314. Protagenic Therapeutics has a twelve month low of $0.23 and a twelve month high of $1.87. The company has a fifty day moving average price of $0.31 and a two-hundred day moving average price of $0.50. The firm has a market cap of $1.63 million, a P/E ratio of -0.18 and a beta of 0.43.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.